In our rectal cancer cohort, we also demonstrated that high DHRS9 immunoexpression is remarkably linked to poor therapeutic response to CCRT and inferior patient survival, suggesting that epithelial cell differentiation may play a role in reducing CCRT efficacy in patients with rectal cancer. The gene discussed is DHRS9; the disease is rectal cancer.